Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis

Bone

Volumn 17, Issue 4, 1995, Pages 383-390

  Adami, S ^a   Passeri, M ^b   Ortolani, S ^c   Broggini, M ^d   Carratelli, L ^e   Caruso, I ^f   Gandolini, G ^g   Gnessi, L ^h   Laurenzi, M ^e   Lombardi, A ⁱ   Norbiato, G ^j   Pryor Tillotson, S ⁱ   Reda, C ⁱ   Romanini, L ^h   Subrizi, D ^h   Wei, L ⁱ   Yates, A J ⁱ  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c IRCCS   (Italy)

^d Ospedale F del Ponte   (Italy)

^e Merck Research Laboratories   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g Italian League for Osteoporosis ^*  (Italy)

^h POLICLINICO UMBERTO I   (Italy)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Alendronate; Amino bisphosphonate; Bone mass; Intranasal salmon calcitonin; Osteoporosis; Postmenopausal

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCIUM ION; OSTEOCALCIN; PYRIDINOL; SALCATONIN;

ABSORPTIOMETRY; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE MASS; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR NECK; GASTROINTESTINAL SYMPTOM; HIP; HUMAN; INTRANASAL DRUG ADMINISTRATION; ITALY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CALCITONIN; CALCIUM, DIETARY; DENSITOMETRY, X-RAY; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FEMUR; FEMUR NECK; HUMANS; ITALY; LONGITUDINAL STUDIES; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE;

EID: 0028846051     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(95)00262-6     Document Type: Article

References (34)

1. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin
2. Aminohydroxybutane bisphosphonate prevents bone loss in a rat model of simulated weightlessness
3. Aminohydroxybutane bisphosphonate and clenbuterol prevent bone changes and retard muscle atrophy respectively in tail-suspended rats
4. Effects of aminohydroxybutane bisphosphonate on bone growth when administered after hind-limb bone loss in tail-suspended rats
5. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates
6. Risks and Benefits of Replacement Estrogen
7. Design of the Fracture Intervention Trial
8. A model of lifetime osteoporosis impact
9. Epidemiology of osteoporosis
10. Bone density at various sites for prediction of hip fractures
11. Predisposition to atherosclerosis in the head, heart, and legs. The framingham study
12. The effect of short term treatment with alendronate on vertical density and biochemical markers of bone remodeling in early postmenopausal women
13. The bone-remodeling transient: Implications for the interpretation of clinical studies of bone mass change
14. Estrogen treatment of patients with established postmenopausal osteoporosis
15. Alendronate prevents or reverses bone loss at the spine and hip in recently menopausal women
16. Long-term fracture prediction by bone mineral density assessed at different skeletal sites
17. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study
18. Nasal salmon calcitonin in osteoporosis
19. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis
20. The prevention and treatment of osteoporosis
21. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
22. Long term effects of a treatment with oral alendronate of postmenopausal osteoporosis
23. Oral alendronate treatment of bone loss in postmenopausal osteopenic women
24. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure
25. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats
26. Comparison of the therapeutic potencies of two bisphosphonates
27. Treatment of postmenopausal osteoporosis with oral alendronate
28. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women
29. The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons
30. The effect of long term alendronate treatment on vertebral strength in ovariectomized baboons and rats
31. Effects of 4-amino- l-hydroxybutylidene bisphosphonate on bone biomechanics in rats
32. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease
33. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD